<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T2" position="float">
 <label>TABLE 2</label>
 <caption>
  <p>Ongoing clinical trials of candidate drugs against SARS-CoV-2 in COVID-19 patients.</p>
 </caption>
 <table frame="hsides" rules="groups" cellspacing="5" cellpadding="5">
  <thead>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Drug</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Cell culture assays</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibition step 
     <italic>in vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Animal assays</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Clinical trials</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Outcomes in clinical trials</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Advantages and/or limitations</td>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Remdesivir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV, MERS-CoV, and SARS-CoV-2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication (RdRp)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibited EBOV and SARS-CoV in both infected mice and monkeys</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Clinical case and clinical trial against SARS-CoV-2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Did not provide antiviral effects or improved clinical outcomes</td>
    <td valign="top" align="left" rowspan="1" colspan="1">This is a multicentre, double-blind, placebo-controlled clinical trial, but more studies might be needed to confirm, since this includes 255 people, and the drug has some adverse effects.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Lopinavir and Ritonavir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV and MERS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication (protease inhibitor)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial with SARS-CoV-2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Did not provide antiviral effects or improved clinical outcomes in severe patients, but, in early infections, clinical outcomes were improved.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">This drug combination is used for other human CoVs, but the study was not multicentre, double-blind, and placebo-controlled. More studies are necessary to confirm, since it had only 199 people and the drug showed some adverse effects.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">IFN-β</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV, MERS-CoV, MHV, and HCoV-229E</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Host Factors (inducing immune response)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV, MERS-CoV, MHV, and HCoV-229E</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial with SARS-CoV-2 and is used for other diseases</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Do not have effect alone</td>
    <td valign="top" align="left" rowspan="1" colspan="1">IFN-β is indicated to be safe, with few adverse effects, but in clinical trials, it is only effective when associated with other drugs.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Umifenovir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Observational study with 81 patients</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Did not provide antiviral effects or improved clinical outcomes</td>
    <td valign="top" align="left" rowspan="1" colspan="1">This is an observational study and might suffer bias from lack and/or loss of information and data. It is an applicable study, since it demonstrates a tendency, and the drug is already used to treat Influenza viruses.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Corsticosteroids (dexamethasone)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Host factors (controlling immune response)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial with 454 treated patients</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Reduced death by one-third in invasive mechanical ventilation patients and one-fifth in oxygen without invasive mechanical ventilation patients; however, did not impair mortality in patients without respiratory support</td>
    <td valign="top" align="left" rowspan="1" colspan="1">This is a multicentre, double-blind, placebo-controlled clinical trial. More studies are needed to understand better the effect on different phases of COVID-19. May be a good alternative for treating hyperinflammation and hypersecretion of cytokines.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Ivermectin</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV-2 and arboviruses (CHIKV and DENV)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication (nonstructural proteins)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Clinical trials are beginning</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ivermectin is safe for use in humans since it is used to treat several parasitic infections.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Tocilizumab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of IL-6</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing clinical trials with SARS-CoV-2 patients; one with 100 patients concluded.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Positive effects: improved inflammatory markers and decreased the need for ventilatory support in patients</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Tocilizumab is already used to treat viral infections, controlling immune response, impairing cytokine storms, improving antiviral response, and providing the best clinical outcomes.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Chloroquine</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibited HIV, CHIKV, SARS-CoV, and SARS-CoV-2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Improved outcomes in FCoV positive cats</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Several clinical trials are being conducted</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Impairs virus replication and has anti-inflammatory activities</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Chloroquine possesses important side effects and is indicated only in severe cases. However, there are some studies with contrasting results regarding its safety, since it can cause arrhythmias, hypoglycemia, neuropsychiatric effects, and depression.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Hydroxychlo-roquine</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibited HIV, CHIKV, SARS-CoV, and SARS-CoV-2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Several clinical trials are being conducted</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Less toxic option, impairs virus replication</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Hydroxychloroquine improved patients’ outcomes, including when associated with azithromycin. Less toxic option than chloroquine treatment, but there are studies with contrasting results regarding its safety, since it can cause arrhythmias, hypoglycemia, neuropsychiatric effects, and depression.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Convalescent Plasma</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Case report</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Improved outcomes and suppressed viremia.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Administration poses a risk to patients since it is related to donor-dependent variability and compatibility. Antibody titers may interfere with its activity. In addition, it might cause side effects in lung and the cardiovascular system.</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <attrib>
   <italic>EC50: effective concentration of 50%; NE: not evaluated.</italic>
  </attrib>
 </table-wrap-foot>
</table-wrap>
